What is Brief History of Green Thumb Company?

GTI secured Illinois medical licenses, opened its first cultivation and processing site, and launched dispensaries that later unified under the RISE retail brand; patient education and consistent product quality produced strong same-store sales as Illinois patient counts expanded to tens of thousands.

The founding team grew from a small group to hundreds across cultivation, manufacturing, retail, and compliance, building the operational backbone needed for multi-state expansion and supporting the founding of Green Thumb and early growth milestones.

GTI completed a reverse takeover and listed on the Canadian Securities Exchange (CSE: GTII) in June 2018, unlocking capital to expand into Pennsylvania, Nevada, Massachusetts and add New Jersey manufacturing capacity ahead of adult-use; revenue exceeded $200 million in 2019 and $500 million in 2020.

Branded portfolios including RYTHM (premium flower and vape), Dogwalkers (pre-rolls) and incredibles (edibles) drove product-market fit; adjusted EBITDA turned positive as scale reduced costs and tight SG&A discipline supported a profitability-oriented trajectory.

With adult-use launches in New Jersey (2022) and Maryland (2023) and maturation in Illinois, GTI increased production and RISE store count toward 80+ locations; revenues approached the $1 billion mark and the company consistently generated positive operating cash flow despite sector-wide IRS 280E challenges.

Facing pricing compression in mature western markets, GTI emphasized brand mix, vertical integration and cost controls to protect margins and maintain disciplined capital allocation and selective M&A activity in line with the Green Thumb company timeline.

GTI sustained annual revenue near $1.1–1.2 billion with adjusted EBITDA above $300 million, strong liquidity (cash in the hundreds of millions) and low net leverage versus peers while investing in live resin, solventless and fast-acting edibles ahead of wider adult-use demand; U.S. rescheduling momentum improved investor sentiment.

GTI reinforced a playbook of disciplined CAPEX, selective tuck-in acquisitions and brand-led retail execution, leveraging a focused MSO strategy to navigate competitive intensity and sustain profitable growth in the evolving cannabis market.

Deepen share in limited-license states and pursue selective entry into high-opportunity adult-use markets such as New York maturation, potential Ohio and Pennsylvania conversions, while maintaining vertical integration where it is margin-accretive.

Focus on premium flower genetics, solventless concentrates and wellness formulations (CBN/CBG blends) plus data-driven assortment optimization to lift gross margin and repeat purchase rates.

Federal rescheduling could eliminate 280E exposure, materially lowering effective tax rates and expanding free cash flow; banking reform or uplisting would reduce the cost of capital and support disciplined M&A or organic growth.

Target steady expansion of RISE locations in high-ROI markets, omnichannel enhancements (loyalty, delivery/express pickup) and broader third-party wholesale penetration to amplify brand reach and margins.

If federal rescheduling finalizes and 2–3 large state conversions occur by 2026, analysts project mid-teens revenue CAGR and 200–400 bps EBITDA margin expansion, reinforcing a profitable-growth leadership position.

Aligned with the founding of Green Thumb and its early years and growth, the company aims to normalize cannabis as a responsible wellness product by scaling trusted brands and compliant operations as the U.S. market formalizes and federal barriers recede; see Competitors Landscape of Green Thumb for related context.